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Abstract 
Endometrial cancer is a common gynecologic malignancy in the United 
States and the recurrence rate depends on stage disease at diagnosis. The 
spread of the disease at recurrence can occur in several areas and follow dif-
ferent patterns. The role of surgery at the time of recurrence is not clearly 
defined. The aim of this review is to fully describe the current evidence 
available on this topic. In particular, we will describe that surgical treatment 
might be recommended for 1) vaginal or pelvic recurrences; 2) retroperito-
neal or localized intra- abdominal recurrence, where a maximal cytoreduc-
tive effort is more likely to be successful; or 3) isolated distant recurrences 
when microscopically tumor-free margins can be achieved. Cases should be 
evaluated individually, considering factors such as comorbidities, risks of 
intervention, and impact of treatment on quality of life. 
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Introduction 
 Neoplasms of the uterine corpus are the fourth most common 
cancer in women. In 2015, an estimated 54,870 new cases of endometrial 
cancer were diagnosed and 10,170 women died of this disease. From 2007 
through 2011, the incidence rate and death rate increased by 2.4% and 1.9% 
per year, respectively, probably because of higher life expectancy and 
increasing incidence of obesity in developed countries (1). 
 Endometrial cancer generally has a favorable prognosis. At 
diagnosis, most women have early stage, low-grade disease, which is 
associated with a 90% 5-year survival rate and an estimated recurrence risk 
of 10% to 15%. However, in women with high-risk histologic findings 
(grade 3 endometrioid adenocarcinoma, papillary serous, clear cell, and 
carcinosarcoma histologic subtypes) or locally advanced disease, the 
biological behavior of the cancer is more aggressive and the prognosis is 
worse, with recurrence rates as high as 50% (2). 
 Recurrence typically develops within 3 years of primary treatment 
(3). After recurrence is diagnosed, the subsequent management strategy 
depends on the site of recurrence, the duration of the disease-free period, the 
general medical condition of the patient, and whether prior adjuvant 
treatment (radiotherapy, chemotherapy, or both) was administered. Patients 
with local recurrence and no previous radiotherapy often receive 
radiotherapy, whereas women with disseminated distant metastasis receive 
systemic treatment (chemotherapy or hormonal therapy). In these settings, 
the role of surgery is poorly defined and data in the literature are scant. Here, 
we review the available literature regarding surgical options and their 
feasibility in recurrent endometrial cancer.  
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Primary Treatment of Endometrial Cancer 
Diagnosis and Staging  
 Postmenopausal bleeding is the most common symptom of 
endometrial cancer, and the diagnosis is usually established by endometrial 
biopsy, or dilatation and curettage, with or without hysteroscopy. For 
clinical staging, preoperative imaging (eg, computed tomography [CT], 
magnetic resonance imaging, or positron emission tomography [PET]) is 
used to determine the presence of extrauterine disease and is generally 
indicated for patients with symptoms or abnormal clinical findings. 
Unfortunately, preoperative imaging studies are generally not accurate for 
detecting microscopic extrauterine metastases (4-6). Surgical staging is the 
diagnostic criterion standard for the identification of extrauterine 
dissemination and is a cornerstone of management of endometrial cancer. 
According to the International Federation of Gynecology and Obstetrics 
staging system, complete staging consists of hysterectomy and bilateral 
salpingo-oophorectomy and may also include pelvic and para-aortic 
lymphadenectomy.  
 
Surgical Approach, Special Situations, and Postsurgical Treatment 
 Traditionally, staging laparotomy is the surgical approach of 
choice for endometrial cancer, but recently, laparoscopic or robot-assisted 
approaches are increasingly used. Randomized controlled trials comparing 
laparoscopic surgery with laparotomy showed similar surgical effectiveness 
without compromising the degree of oncologic radicality (7,8). Furthermore, 
robotic surgery may show outcomes similar to those of laparoscopy (9,10). 
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Table 1 shows suggested surgical procedures for primary and recurrent 
endometrial cancer. 
 After surgical staging, adjuvant therapy (systemic chemotherapy, 
radiotherapy, or a combination) may be indicated for patients with 
advanced-stage disease or those with tumors confined to the uterus but with 
associated risks factors (11).  
Patterns of Dissemination and Recurrence 
 The overall rate of recurrence for endometrial cancer is about 10% 
to 15%, with more than half of failures occurring within 3 years of primary 
treatment (3). Recurrence rates are higher in patients with advanced-stage 
disease and those with aggressive histologic subtypes (grade 3 or 
nonendometrioid) (3). Most women are symptomatic at the time of 
recurrence, and the most common symptoms are bleeding (from the vagina, 
bladder, or rectum), anorexia, weight loss, bone or pelvic pain, cough, 
shortness of breath, or lower abdominal or extremity swelling (12). 
 The diagnostic evaluation of suspected recurrent disease includes 
a pelvic examination with possible biopsies of clinically suspicious areas; a 
physical examination focused on nodal regions; and radiologic imaging to 
determine whether metastatic disease is present. CT is often the primary 
imaging modality used to evaluate potential recurrence; if the scan is 
equivocal, further evaluation with PET or combined PET-CT may be 
indicated (11). 
 Recurrent endometrial cancer disseminates via 4 main routes: 
contiguous, lymphatic, peritoneal, and hematogenous (Table 2) (14). The 
pattern of metastasis can be attributed to 1 route alone or a combination. As 
an example, in an unselected population of 915 patients (without history of 
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other malignancies) who received treatment for endometrial cancer during a 
13-year period, the relapse rates were 5% for vaginal, 9% for hematogenous, 
6% for lymphatic, and 6% for peritoneal pathways of dissemination (14) 
(Figure 1). 
 From a clinical perspective, recurrence can be organized into 4 
patterns: 
 1. Isolated vaginal recurrence (or central recurrence) is defined as 
an isolated recurrence involving the vaginal vault or cuff  
 2. Central pelvic recurrence (or locoregional recurrence) is typi-
cally recurrent disease affecting pelvic structures such as the vulva, vagina, 
lower urinary tract, and rectosigmoid colon  
 3. Lateral-pelvic recurrence or pelvic sidewall recurrence is a 
lymphatic recurrence along the major vessels of the pelvic side wall 
 4. Distant extrapelvic recurrence (eg, in the abdominal retroperi-
toneum, lung, brain, or other distant sites) is often multifocal 
 The management strategy for patients with recurrence depends on 
the site of recurrence, the duration of the disease-free period, the general 
medical condition of the patient (including Performance Status), and 
whether prior adjuvant treatment (radiotherapy, chemotherapy, or both) was 
administered (Figure 2). Women with recurrent disease isolated to the 
vaginal vault are potentially curable (15). Options for treatment depend on 
whether radiotherapy was previously administered. If radiotherapy was not 
administered previously, it is the treatment of choice. If radiotherapy was 
administered, radical surgery is an option for select candidates. Similarly, in 
women with locally recurrent disease limited to the central pelvis, treatment 
options potentially are curative and include surgery or radiotherapy 
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(including intraoperative radiotherapy [IORT] for lateral recurrences). In 
women with extrapelvic disease, treatment usually is not curative and the 
approach should be individualized (11,16). 
 Despite the above indications, the role of surgery in recurrent 
endometrial cancer is rarely mentioned in the literature. Current guidelines 
from the United States (National Comprehensive Cancer Network ), Canada 
(Alberta Provincial Gynecologic Oncology Tumour Team), and Europe 
(European Society for Medical Oncology) recommend a surgical approach 
for women with isolated vaginal or pelvic recurrence and a history of 
radiotherapy, but the recommendation is supported by only low-level 
evidence (11,16,17). For distant metastases, available data are from case 
reports or small series, so indications are only weakly supported. 
In patients with multiple recurrence sites, usually surgery is not considered 
as a feasible option. However, in few selected cases, it could be taken into 
account especially if the performance status of the patients is good and the 
lesions are resectable with no residual tumor left. 
 Options for surgical management of endometrial cancer, 
depending on the pattern of recurrence, are described below. We emphasize 
that the most favorable surgical candidates have a good performance status 
and a long interval without endometrial cancer or any other systemic 
disease; additionally, they must have resectable disease with the potential to 
achieve microscopically tumor-free margins. A multidisciplinary approach is 
however mandatory in order to tailor therapies. 
Figures from 3 to 6 and Table 3 summarize the surgical options for every 
site of recurrence. 
Isolated Vaginal and Locoregional Recurrence 
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 Women who have undergone surgery for endometrial cancer are 
at risk of relapse in the vaginal vault; this 8-year risk of relapse is lower in 
those who received adjuvant external radiotherapy (2% vs 8% for 
radiotherapy vs no-radiotherapy groups, respectively) or with vaginal 
brachytherapy (18). Prognosis is usually better in patients with isolated 
vaginal vault recurrence compared with patients with relapse in other pelvic 
structures (3-year overall survival rate, 73% vs 8%; P<.001) (19). 
 For patients with a suspected local recurrence (either isolated 
vaginal or locoregional), radiologic imaging should be performed to exclude 
other sites of metastasis. The modality considered to be most accurate is 
integrated PET-CT. If no distant metastases are found, the treatment 
approach considers whether radiotherapy was previously administered 
(Figure 3). 
 Radiotherapy is the standard treatment for women with isolated 
vaginal recurrence and no history of radiotherapy; the complete response 
rate is 87% (19). Chemotherapy and surgery can be used in select patients 
with local extension of the disease or a large-diameter recurrence. For 
women who have previously received adjuvant radiotherapy, the prognosis 
is poorer and treatment recommendations vary among institutions. Repeat 
radiotherapy might be an option in select cases (20), whereas radical surgical 
resection, sometimes combined with IORT, might be proposed for 
appropriate surgical candidates (21). 
 Historically, in surgery-eligible patients with recurrence limited to 
the vaginal apex within an irradiated field, the surgical approach is pelvic 
exenteration (22,23). Total exenteration refers to removal of the uterus, 
fallopian tubes, ovaries (if still present), parametrium, bladder, rectum or 
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rectal segment, vagina, urethra, and a portion of the levator muscles. In the 
anterior exenteration, the rectum is spared, whereas in the posterior 
exenteration, the bladder and urethra are preserved. A perineal phase, with 
resection of the anus, urethra, and portions of the vulva, may also be 
required. Other classifications of pelvic exenteration are supralevator and 
infralevator. Supralevator exenteration includes removal of the bladder, 
upper vagina, cervix, uterus, and rectosigmoid colon, while preserving the 
pelvic floor. In infralevator exenteration, removal of the pelvic floor muscles 
is indicated if the disease involves the lower part of the vagina, vulva, 
perineum, or anus; reconstruction with myocutaneous flaps, omental flap, or 
dura mater has been performed to address the large pelvic defect (24).  
 The choice of procedure depends on the location of the cancer, 
difficulties that may arise during surgery, type and location of previous 
radiotherapy, anatomy, and the patient’s postoperative goals and 
expectations. A recent review by Ang et al (25) indicated that no high-level 
evidence was available to guide women with recurrent cervical, endometrial, 
vaginal, or vulvar malignancies in decisions about exenterative surgery. No 
randomized studies have determined whether exenterative surgery is 
superior to nonsurgical treatment in terms of prolonged survival, treatment-
related complications, or quality of life (25).  
 In a retrospective cohort study of patients who underwent pelvic 
exenteration after recurrent endometrial neoplasm, Westin et al (26) 
described a 5-year relapse-free survival rate of 45% and a 5-year overall 
survival rate of 56%. Other series have described similar 5-year overall 
survival rates (27-33).  
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The potential complications after pelvic exenteration are numerous and 
should be taken into account at time of decision. The major early postopera-
tive complications include blood loss, sepsis, wound dehiscence, and anas-
tomotic breakdown at the level of the bowel, urinary pouch, or ureteral sites. 
Late complications include fistula, bowel obstruction, ureteral strictures, re-
nal failure, pyelonephritis, and chronic bowel obstructions. 
Other complications include deep venous thrombosis and pulmonary emboli, 
flap necrosis, and stomal necrosis. (34-35) 
Despite improvements in patient selection and surgical techniques, overall 
survival rates have not changed meaningfully over time, and rates of long-
term complications have remained steadily high (26). Therefore, because 
short- and long-term sequelae of treatments might have a significant and 
negative impact on a patient’s quality of life, and considering that surgical 
exenteration is a mutilating procedure, great effort should be made in the 
preoperative setting to accurately inform the patient and provide 
psychological support. 
Lymphatic Spread 
Retroperitoneal Disease  
 Many endometrial cancers recur within the pelvic sidewall or retro-
peritoneum through lymphatic embolization (Figure 4). Pelvic and para-
aortic lymph nodes are most commonly involved in nodal spread. External 
iliac lymph nodes are the most commonly involved pelvic lymph nodes, fol-
lowed by the obturator and common iliac nodes. Lymphatic recurrences, 
which are generally poorly differentiated, do not respond to hormonal thera-
py and respond poorly to multiagent chemotherapy (18). Recurrence in the 
pelvic sidewall or lymph node−bearing areas is associated with 3-year sur-
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vival rates of less than 10% after radiotherapy, and local secondary recur-
rence rates may be as high as 100% (18).  
 A case series of 25 patients with retroperitoneal recurrences, 
reported an aggressive treatment approach with preoperative radiation, 
radical surgical resection, and intraoperative radiotherapy (36). The 
objective was to determine whether this approach maximized tumor control 
and decreased complications compared with radiotherapy alone. The overall 
5-year survival was 47% (median survival, 57 months). Patients with a gross 
total resection and negative margins had a 5-year survival rate of 71%, 
which was much better than patients with gross or microscopic residual 
disease (0% and 40%, respectively). This finding underscores the 
importance of achieving gross total resection.  
 The morbidity rate of radical procedures is high (64%) (36). 
Possible complications include pulmonary embolism, acute lower-extremity 
ischemia, small-bowel and functional ureteral obstruction, and fistulas. 
Nevertheless, given that tumor-related mortality rates in the absence of 
treatment are nearly 100%, radical procedures should be considered; 
however, their high rates of morbidity must be discussed preoperatively with 
the patient. 
Isolated Distant Nodal Recurrences 
 First recurrences in an inguinal, axillary, or supraclavicular node 
as an isolated site are extremely rare. Twenty two patients with such a 
recurrence were reported in a case series; of these, 7 were treated with 
excision and aggressive local irradiation and achieved local control of the 
nodal recurrence. Although the median survival after isolated peripheral 
lymph node recurrence was only 19 months, 6 patients were alive without 
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evidence of cancer at a median follow-up of 27 months (37). Even if an 
associated effective systemic adjuvant treatment is usually needed, in 
patients with isolated peripheral nodal recurrences, this series showed that 
aggressive local treatment can provide long-term, disease-free survival.  
Peritoneal Recurrences 
 Peritoneal carcinomatosis is a common type of recurrent 
endometrial carcinoma (Figure 5), accounting for 28% of relapses. This 
pattern of recurrence is generally associated with a poor prognosis (14,38). 
Recurrences may be large peritoneal masses, peritoneal nodules, and serosal 
implants that may cause extrinsic compression of the bowel. 
The meta-analysis by Barlin et al (39) suggests that among patients 
with recurrent or advanced endometrial cancer, surgical cytoreduction to no 
gross residual disease may confer a survival advantage. Papadia et al (40) 
reported complete resection to no visible disease in 42 of 64 cases of EC 
(66%) that underwent cytoreductive surgery for recurrence, and according to 
the studies considered in the review by Barlin et al (40), they reported simi-
lar 5-year rates of RFS and OS (34% and 51%, respectively).  
 Any residual disease (microscopic or gross) after cytoreductive 
surgery is considered a failed surgical treatment. Some patients with 
microscopic residual disease have undergone cytoreductive surgery and 
received hyperthermic intraperitoneal chemotherapy; however, available 
data are based on only a few patients, and no consistent conclusion about the 
benefits of this procedure can be drawn (41). 
In conclusion, cytoreductive surgery in peritoneal recurrences is indicated if 
patient has a good preoperative performance status without comorbidities 
that might contraindicate the procedure itself, and if complete resection of 
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macroscopic disease is achievable. When complete removal of the disease is 
not achievable but a maximum extent of surgery will improve patients 
quality of life (for example, in cases of bowel obstruction), surgical 
approach is indicated as a palliative treatment. 
 
Hematogenous Dissemination 
 Hematogenous recurrence can affect the brain, lungs, liver, and 
bone (Figure 6).  
Lung  
 The incidence of pulmonary metastasis for patients with 
endometrial cancer ranges from 2.3% to 7%. Stage IV disease and 
myometrial invasion exceeding 50% are the strongest predictors of lung 
failure. Nodules are frequently multiple and bilateral, but a solitary nodule 
may also occur.  
 With lung metastases, the prognosis is generally poor. However, 
hematogenous dissemination to the lungs tends to occur in elderly patients 
with low-grade tumors; this finding might indicate a spectrum of tumor 
behavior, with lung metastasis indicating less-aggressive behavior compared 
with tumors having hematogenous dissemination to other sites (42). Criteria 
for determining eligibility for surgical resection of pulmonary metastases are 
shown in the Box. 
 From the literature, predictors of survival in patients with isolated 
lung metastases are length of the disease-free interval and number of 
cancerous pulmonary nodes. In a series of 28 cases, the following 
characteristics predicted favorable outcome: grade 1 or 2 tumors, greatest 
diameter of pulmonary nodule ≤2 cm, nonchemotherapy treatment, and 
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estrogen receptor−positive status. Although chemotherapy was associated 
with reduced survival, outcomes were similar among patients treated with 
surgical resection vs those receiving progestational therapy. Considering the 
most favorable risk:benefit ratio of administration of progestational therapy 
vs thoracotomy, hormonal therapy is a reasonable consideration, at least as a 
first-line treatment for patients with low-grade tumors (43).  
Even if data in the Literature are available on the role of stereotactic radio 
surgery in primary lung cancer, only very limited information is available on 
its role in metastatic or recurrent gynecologic cancer. for this reason, no 
conclusions can be drawn about efficacy and long term effects.  (44) 
 
Bone  
 Bone metastases in endometrial cancer are less common, with an 
overall incidence rate less than 1%. The spine and hip are the most common 
sites of osseous dissemination, and the 5-year survival rate after diagnosis of 
bone dissemination is extremely poor (1%) in the setting of recurrent 
disease. However, the prognosis is better when bone metastases are 
discovered at presentation (45). 
 No consensus exists on the best elective treatment of bone 
metastases, and multimodal therapies are usually administered. Surgery can 
be considered for patients with impending or existing pathologic fractures, 
spinal cord compression, and pain, especially in the setting of resistance to 
radiotherapy. Surgical options include 1) wide resection (consisting of en 
bloc removal of the bone lesion with an envelope of normal tissue, followed 
by reconstruction); 2) intralesional curettage followed by internal fixation; 
and 3) palliative decompression of the spinal cord (46). 
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 Although surgical excision of the metastasis is an option, little in 
the literature describes the impact of this treatment on survival. Thus, no 
definite conclusions can be drawn, and multimodal therapies are usually 
required. 
Brain  
 Brain metastases in patients with endometrial cancer are rare 
(estimated prevalence, 0.86%). Prognosis is poor, and the median overall 
survival after diagnosis is 6.5 months (unpublished data). Because of the low 
prevalence of brain metastasis, radiologic examination of the brain is not 
universally recommended for patients with endometrial cancer. Diagnosis is 
usually established by imaging tests after the onset of symptoms (eg, limb 
paresis, refractory headache).  
 During the past decade, we have observed a controversial 
evolution in the treatment of brain metastasis. Previously, surgical resection 
followed by whole-brain radiotherapy (WBRT) was considered the best 
treatment for a solitary metastasis (47). Moreover, WBRT was used in all 
patients with brain metastases, independent of the number of metastases. 
However, because of its detrimental effects on cognition and quality of life, 
during the past few years, the role of WBRT has been questioned, and some 
have suggested stereotactic radiosurgery to treat patients with limited brain 
metastasis (48). Furthermore, a recent multicenter prospective study 
concluded that stereotactic radiosurgery alone should be considered in 
patients with up to 5 to 10 brain metastases (49). In contrast, other authors 
still recommend WBRT with surgical resection in patients with good 
performance status and limited extracranial disease (50,51). Thus, given the 
recent considerations, the role of the surgery now is limited to 2 main 
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indications: 1) to confirm the diagnosis when it is in doubt and 2) to alleviate 
the mass effect in patients with large tumors. The treatment of brain 
metastasis should be individualized on the basis of the burden of disease at 
diagnosis and by considering how to minimize cognitive dysfunction and 
negative effects on quality of life, without affecting survival outcome.  
Liver and Intra-abdominal Organs  
 The most common intra-abdominal organ affected by 
hematogenous endometrial metastasis is the liver (7%), followed by the 
adrenal glands and the spleen (1%) (38). Indications for hepatic resection of 
gynecologic tumors generally are the same as those for the resection of 
colorectal metastases: 1) the patient must be medically fit to undergo major 
abdominal surgery; 2) unresectable extrahepatic tumors must not be visible 
with preoperative imaging; and 3) grossly negative resection margins must 
be achievable while still leaving an adequate volume of functional liver. 
 Because most hepatic recurrences are generally associated with 
other distant disease (42), few reports have described hepatic metastases 
resection and splenectomy in the setting of recurrent endometrial cancer. 
Thus, no definitive conclusions can be drawn about the efficacy of the 
procedure in terms of survival. Also, multimodal therapy should be 
delivered after the procedure because occult microscopic systemic 
dissemination of the disease might be present (52). 
Expert Commentary 
 Treatment options for patients with recurrent endometrial cancer 
include radiotherapy, chemotherapy, hormonal therapy, and surgery, 
depending on the type and localization of the recurrence, patient functional 
status, presence of other associated disseminated disease, duration of the 
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disease-free survival period, and the intent of the treatment itself (ie, curative 
or palliative). Data from retrospective series suggest that surgery can be 
considered for select patients with recurrent endometrial cancer. The main 
factor to consider when evaluating a patient’s eligibility for surgery is the 
feasibility of completely resecting the disease. Even if subsequent systemic 
treatments are administered after surgery, the prognostic factor with the 
greatest effect on survival rates is complete resection of the lesions 
(including resection of associated distant residual disease). Complete 
cytoreduction can be achieved in many patients with a single isolated 
metastasis (even at distant sites), but it may be more difficult to achieve in 
patients with diffuse intraperitoneal or retroperitoneal disease. Furthermore, 
because patients with recurrent endometrial cancer usually are affected by 
several comorbidities, an accurate preoperative evaluation must be 
undertaken to appropriately weigh the possible risks to the patient if radical 
surgery is planned. Quality of life should also be considered for the more 
radical procedures.  
Five-Year View 
 Our recommendation for surgery in recurrent endometrial cancer 
is mostly limited to patients with locoregional relapse, especially those who 
previously received radiotherapy. The surgical excision of disease located in 
other areas is often more dependent on physician preference or surgical skill 
than on evidence-based indications. In fact, some patterns of recurrence are 
extremely rare, and evidence-based recommendations do not exist. Ideally, 
the complete eradication of the disease at relapse should be achieved with 
minimal impact on the patient’s quality of life. A multimodal approach that 
integrates highly skilled surgery, radiotherapy, and medical therapy can be 
   -20- 
 
considered; such an approach also should be investigated in future research. 
Tailoring adjuvant therapies to tumor and patient characteristics, possibly 
with molecular-based therapy, must be the goal of future research (53). 
Key Issues 
  Endometrial cancer has 4 pathways of dissemination (contiguous, 
lymphatic, hematogenous, and peritoneal) 
  The pattern of recurrence, patient functional status, and prior adjuvant 
treatment status are instrumental for defining the optimal management 
strategy and determining the need for surgery 
  If surgery is performed for recurrent endometrial cancer, the aim 
should be macroscopic complete resection 
  After local recurrence, surgical resection (pelvic exenteration) is 
indicated in operative candidates; usual candidates for exenteration 
are patients who previously received radiotherapy and present with 
isolated central local recurrence 
  In patients with retroperitoneal or intraperitoneal recurrence, 
cytoreductive surgery with maximum effort to no residual disease 
improves overall survival 
  Intraoperative radiotherapy may be useful in patients with 
retroperitoneal recurrence; in fact, recurrences affecting the large 
pelvic or para-aortic vessels are more likely to be excised, leaving 
microscopic or macroscopic residual disease 
  In distant recurrences (eg, bone, brain, lung, liver), surgical resection 
is feasible in select patients with limited disease; however, no 
evidence-based data suggesting improvement of survival are available 
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  Morbidity rates and quality of life must always be considered before 
radical surgery is performed  
  Randomized trials in surgery for recurrent endometrial cancer are 
certainly needed but are difficult to perform; thus, a homogeneous 
case series of patients (homogenous in terms of patients 
characteristics, disease characteristics, and standardized uniform 
treatment) may help define the best treatment 
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Table 1. Surgery in EC 
Type of Surgery Procedure 
Primary surgery  
Type 1 endometrioid 
cancer 
Total hysterectomy, bilateral sal-
pingo-oophorectomy, pelvic and 
para-aortic lymphadenectomy 
(depending on preoperative and 
intraoperative findings), biopsy of 
any suspect lesions 
Peritoneal cytology (optional) 
Type 2 EC Peritoneal biopsies, total hysterec-
tomy, bilateral salpingo-
oophorectomy, pelvic and para-
aortic lymphadenectomy, 
omentectomy, biopsy of any sus-
pect lesions 
At recurrence Total pelvic exenteration (or radical 
pelvic surgery) 
Surgical cytoreduction to no gross 
residual disease 




Abbreviation: EC, endometrial cancer. 
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Table 2. Patterns of Recurrence 
Recurrence Type Affected Area 
Contiguous  
Isolated Vaginal vault, vaginal cuff 
Local extension beyond the 
uterus (locoregional) 




Spread through the lymphatic 
system 
Pelvic and para-aortic nodes, ingui-
nal nodes, axillary nodes, supra-
clavicular nodes, mediastinal 
nodes 
Peritoneal (or spread along the peri-
toneal cavity) 
Intraperitoneal implants, peritoneal 
carcinomatosis 
Hematogenous (or spread through 
the vascular system) 
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Box. Criteria for Determining Eligibility for Surgical Resection of Pulmo-
nary Metastases 
1) The primary tumor site should be free of disease  
2) Metastases should be confined to the lungs 
3) Total removal of disease must be feasible (the absolute number of metas-
tases per se is not discriminatory) 
4) Chemotherapy or hormonal therapy will not be curative, and other more 
effective therapies are unavailable  
5) The patient can tolerate surgical therapy, and pulmonary function is com-
patible with the proposed resection  
6) Total removal of all disease must be possible 
 
 
(Adapted from Dresler and Goldberg. Surgical management of lung metasta-
ses: selection factors and results. Oncology [Williston Park]. 1996 
May;10[5]:649-55. Used with permission.) 
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Legends 
Figure 1. Patterns of recurrences in endometrial cancer. Of all recurrences, 
48% had a hematogenous component (21% were isolated hematogenous 
recurrences), 32% had lymphatic component (16% were isolated lymphatic 
recurrences), 33% had peritoneal component (18% were isolated peritoneal 
recurrences), and 18% had isolated vaginal recurrences. Approximately 27% 
of recurrences had multiple components of recurrence. Adapted from 
Mariani et al (17). Used with permission. 
Figure 2. Treatment options for locoregional recurrences. IORT indicates 
intraoperative radiotherapy; PET-CT, positron emission 
tomography−computed tomography; RT, radiotherapy. 
Figure 3. Summary of surgical options, inclusion criteria, recommendation 
grade, and other treatments for contiguous recurrences. CHT indicates 
chemotherapy; EBRT, external beam radiotherapy; GoR, grade of 
recommendation; HIPEC, hyperthermic intraperitoneal chemotherapy; 
IORT, intraoperative radiotherapy; PET-CT, positron emission 
tomography−computed tomography; RT, radiotherapy. 
Figure 4. Summary of surgical options, inclusion criteria, recommendation 
grade, and other treatments for lymphatic recurrences. Abbreviations are 
defined in the Figure 3 legend. 
Figure 5. Summary of surgical options, inclusion criteria, recommendation 
grade, and other treatments for peritoneal recurrences. Abbreviations are 
defined in the Figure 3 legend. 
Figure 6. Summary of surgical options, inclusion criteria, recommendation 
grade, and other treatments for hematogenous recurrences. Abbreviations are 
defined in the Figure 3 legend. 
